<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Healtheuniverse Inc — News on 6ix</title>
    <link>https://6ix.com/company/healtheuniverse-inc</link>
    <description>Latest news and press releases for Healtheuniverse Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sat, 21 Jun 2025 12:40:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/healtheuniverse-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine</title>
      <link>https://6ix.com/company/healtheuniverse-inc/news/new-data-from-phase-iii-trial-confirms-efficacy-of-vyeptir-eptinezumab-in-asian-population-with-chronic-migraine</link>
      <guid isPermaLink="true">https://6ix.com/company/healtheuniverse-inc/news/new-data-from-phase-iii-trial-confirms-efficacy-of-vyeptir-eptinezumab-in-asian-population-with-chronic-migraine</guid>
      <pubDate>Sat, 21 Jun 2025 12:40:00 GMT</pubDate>
      <description>H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1</description>
    </item>
    <item>
      <title>SEC Order Of Suspension Of Trading</title>
      <link>https://6ix.com/company/healtheuniverse-inc/news/sec-order-of-suspension-of-trading-15</link>
      <guid isPermaLink="true">https://6ix.com/company/healtheuniverse-inc/news/sec-order-of-suspension-of-trading-15</guid>
      <pubDate>Thu, 08 Mar 2007 21:07:26 GMT</pubDate>
      <description>SEC Order Of Suspension Of Trading.</description>
    </item>
  </channel>
</rss>